LivaNova PLC (NASDAQ:LIVN), a medical technology firm, reported second-quarter 2025 results on Wednesday that exceeded analyst forecasts, showcasing robust growth across its business units and boosting its full-year guidance.
The company posted adjusted earnings per share of $1.05, well above the consensus estimate of $0.87. Revenue totaled $352.5 million, surpassing the expected $332.21 million and marking a 10.7% increase year-over-year on a reported basis. Organic revenue growth was 10.3%.
Growth was led by the Cardiopulmonary segment, which saw revenue rise 14.7% to $199.3 million, fueled by strong demand for consumables and sales of the Essenz Perfusion System globally. The Neuromodulation segment also contributed, with revenue up 6.2% to $151.7 million.
“LivaNova delivered another quarter of strong revenue growth, driven by continued momentum in our Cardiopulmonary business and solid Neuromodulation performance across all regions,” said CEO Vladimir Makatsaria. “Our disciplined execution contributed to meaningful operating margin expansion and strong cash generation in the second quarter.”
The company raised its 2025 full-year revenue growth forecast to 8.0%-9.0% on a constant-currency basis and 9.0%-10.0% organically, an increase of 200 basis points from prior guidance. Adjusted earnings per share guidance was lifted to a range of $3.70 to $3.80, above the analyst consensus of $3.65.
LivaNova also made progress in treatment innovation, initiating the U.S. Medicare reconsideration process for VNS Therapy coverage for treatment-resistant depression, supported by five peer-reviewed publications from the RECOVER study.
During the quarter, the company generated $47.8 million in adjusted free cash flow, reflecting strong operational performance and financial discipline.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.